Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma has been awarded the 2025 SwedenBIO Award, recognizing the company’s role in converting Swedish scientific excellence into global medical impact through its pioneering enzyme technology that enables life-saving transplantation for highly sensitized patients. The accolade underscores Hansa’s growing international profile and momentum going into 2026, as it advances strong U.S. Phase 3 data, prepares for an FDA review, and anticipates a key Phase 3 readout from its European trial later this year—developments that could further strengthen both the company’s commercial position and Sweden’s standing as a leader in life science innovation.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies for patients with acute or complex immune disorders. Built around a proprietary IgG‑cleaving enzyme technology platform, its portfolio targets serious unmet medical needs in transplantation, gene therapy and autoimmune diseases, including the first-in-class IgG antibody‑cleaving enzyme imlifidase, which enables kidney transplantation in highly sensitized patients, and next-generation candidate HNSA-5487 for Guillain-Barré Syndrome. Headquartered in Lund, Sweden, Hansa operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.
Average Trading Volume: 631,309
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.27B
See more data about HNSA stock on TipRanks’ Stock Analysis page.